Main Patient Populations in Sapropterin Trials
Sapropterin (Kuvan), approved for treating hyperphenylalaninemia due to tetrahydrobiopterin (BH4)-responsive phenylketonuria (PKU), was primarily tested in clinical trials on patients with PKU aged 4 years and older who showed blood phenylalanine (Phe) reductions of at least 30% on a Phe-restricted diet.[1]
Key trials focused on:
- BH4-responsive PKU patients: Pivotal studies like the Phase 3 trial enrolled 242 patients (ages 8-50) with Phe levels between 10-30 mg/dL, confirming responsiveness via a 24-hour challenge test.[2]
- Pediatric extensions: Long-term open-label studies included children as young as 4 years, assessing sustained Phe control and growth.[3]
Trials in Infants and Younger Children
A dedicated Phase 3 trial (PKU-008) targeted BH4-responsive PKU infants aged 1 month to 6 years (n=93), evaluating safety, Phe control, and neurodevelopment on sapropterin plus diet. This supported 2018 FDA approval for ages 1 month and older.[4]
Trials for Other Hyperphenylalaninemia Types
Exploratory studies examined sapropterin in:
- Tetrahydrobiopterin (BH4) deficiencies: Small open-label trials (n=15-30) in patients with 6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency or dihydropteridine reductase (DHPR) deficiency, showing partial BH4 responsiveness.[5]
- Non-PKU hyperphenylalaninemia: Limited data from compassionate-use programs, but not leading to broad approval.[1]
Exclusion Criteria and Limitations Across Trials
Most trials excluded patients with:
- Phe levels >30 mg/dL at baseline.
- Concomitant conditions like renal impairment or malignancy.
- Non-responders (less than 30% Phe drop post-challenge).[2][3]
No large-scale trials occurred in pregnant patients or those with severe liver disease.[1]
Ongoing or Expanded Research Populations
Post-approval studies explore sapropterin in:
- Adolescents and adults with milder PKU variants.
- Combination therapies for broader hyperphenylalaninemia, though evidence remains limited.[6]
[1]: FDA Label for Kuvan (sapropterin)
[2]: NEJM 2007: Phase 3 PKU Trial
[3]: Mol Genet Metab 2010: Pediatric Extension Study
[4]: Pediatrics 2019: Infant PKU Trial (PKU-008)
[5]: J Inherit Metab Dis 2011: BH4 Deficiency Review
[6]: ClinicalTrials.gov: Sapropterin Studies